Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Selinexor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Malaysia Approves Antengene's XPOVIO for DLBCL Treatment
    Malaysia Approves Antengene's XPOVIO for DLBCL Treatment

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643379.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Karyopharm Reveals Q3 2025 Financials And Company Advancements
    Karyopharm Reveals Q3 2025 Financials And Company Advancements

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-third-quarter-2025-financial-results-and-highlights-recent-company-progress-302601720.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Karyopharm Completes Ph3 SENTRY Trial Enrollment in Myelofibrosis
    Karyopharm Completes Ph3 SENTRY Trial Enrollment in Myelofibrosis

    10 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-completion-of-enrollment-in-the-phase-3-sentry-trial-in-myelofibrosis-302551682.html

    PR NEWSWIRE
    10 Sep 2025
    Share Share
    Karyopharm presents Selinexor in Myelofibrosis at 2025 EHA Meeting
    Karyopharm presents Selinexor in Myelofibrosis at 2025 EHA Meeting

    14 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-poster-presentation-on-selinexor-in-myelofibrosis-at-the-2025-european-hematology-association-annual-meeting-302454678.html

    PR NEWSWIRE
    14 May 2025
    Share Share
    Karyopharm Reports Q1 2025 Results and New Data in Myelofibrosis
    Karyopharm Reports Q1 2025 Results and New Data in Myelofibrosis

    12 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-first-quarter-2025-financial-results-and-announces-new-data-in-myelofibrosis-that-further-suggests-selinexor-may-lead-to-meaningful-spleen-volume-reduction-symptom-improvement-hemoglobin-stabilization-and-dise-302452744.html

    PR NEWSWIRE
    12 May 2025
    Share Share
    Xpovio Approved for Commercialization in Indonesia,
    Xpovio Approved for Commercialization in Indonesia,

    04 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xpovio-selinexor-approved-for-commercialization-in-indonesia-further-expanding-antengenes-commercial-presence-in-apac-302392606.html

    PR NEWSWIRE
    04 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.